GTS Securities’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q4
Sell
-421,000
Closed -$28.1M 3017
2024
Q3
$28.1M Buy
421,000
+175,900
+72% +$16.1M 0.06% 189
2024
Q2
$29.1M Sell
245,100
-58,700
-19% -$7.43M 0.06% 187
2024
Q1
$32.4M Sell
303,800
-99,600
-25% -$10M 0.06% 169
2023
Q4
$40.1M Sell
403,400
-16,100
-4% -$1.35M 0.07% 168
2023
Q3
$43.3M Buy
+419,500
New +$46.8M 0.08% 139

Other funds holding MRNA

GTS Securities's MRNA Position: Q2 2025 in Review

GTS Securities sold out of Moderna (MRNA) in Q2 2025, closing a stake of 21,737 shares — an estimated $616K sold.

GTS Securities first reported a position in MRNA in Q2 2023 and held it in 7 quarters. The position peaked at $16M in Q3 2023. 674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

  • GTS Securities reported no remaining Moderna position as of Q2 2025 after selling out during the quarter.
  • GTS Securities sold 21,737 Moderna shares in Q2 2025, an estimated $616K.
  • GTS Securities first reported a position in Moderna in Q2 2023 and held it in 7 quarters.
  • GTS Securities's Moderna position peaked at $16M in Q3 2023.
  • 674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on GTS Securities's 13F filing for Q2 2025, filed 8 Aug 2025.